BioCentury
ARTICLE | Financial News

Aimmune raises $160M in bumped-up IPO

August 7, 2015 2:03 AM UTC

Aimmune Therapeutics Inc. (NASDAQ:AIMT) gained $8.10 (51%) to $24.10 in its first day of trading Thursday after it raised $160 million through the sale of 10 million shares at $16 in an IPO underwritten by BofA Merrill Lylnch; Credit Suisse; and Piper Jaffray. The offering price valued Aimmune at $650.9 million. Aimmune ended the day with a market cap of $980.4 million.

Aimmune filed last month to raise up to $115 million. Earlier this week, the company said it hoped to sell 8.3 million shares at $14-$16. At $15, it would have raised $125 million and been valued at $585.3 million. ...